Kymera Therapeutics, Inc. (KYMR) Q2 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good day, everyone. My name is Olivia and I will be your conference operator today. At this time, I would like to welcome you to the Chimera Therapeutics second quarter 2025 results call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there'll be a question and answer session. If you would like to ask a question during this time, and if you have joined via the webinar, please use the raise hand icon, which can be found at the bottom of your webinar application. If you have joined by phone, please dial star nine on your keypad to raise your hand. At this time, I would like to turn the call over to Bruce Jacobs, Chief Financial Officer. Good morning. I'm Bruce Jacobs, and I'm kicking off this in place of Justine Konigsberg, our head of IR, who is out today. Joining me this morning are Nella Manolfi, founder, president, and CEO, and Jared Golub, our chief medical officer. Following our prepared remarks, we'll open the call to questions from our publishing analysts. If you'd like to ask a question, please use the raised hand icon, which can be found at the bottom of your meeting window. And to help us move efficiently through the Q&A session, we ask that you're ready to unmute your line when called upon. In addition, we ask that you please limit your question to one and a relevant follow-on to be sure we have enough time to address everyone's questions this morning. Before we begin, I'd like to remind you that today's discussion will include forward-looking statements about our future expectations, plans, and prospects. These statements are subject to risks and uncertainties that may cause actual results to differ materially from those projected. The description of these risks can be found in our most recent 10Q filed wit...